Alzamend Neuro

ALZNNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$9.362 M

$1.94 +2.65%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$8.77M

Loss-making

Shares outstanding

4,791,525

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#434Moleculin BiotechMBRX$10.1M
#435ImmuronIMRN$10.0M
#436Alzamend NeuroALZN$9.36M
#437Aprea TherapeuticsAPRE$9.28M
#438BullFrog AIBFRG$9.14M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Alzamend Neuro, worth $221.9K. Grants and option exercises are excluded.

Milton C. Ault III$111.0K
110,388 shares at $1.01 on 14 Apr 2026 · filed 31 Aug 2026
Milton C. Ault III$111.0K
110,388 shares at $1.01 on 14 Apr 2026 · filed 31 Aug 2026

What if Alzamend Neuro were worth as much as…

Open the what-if tool →

Gold $30.3T

$6,273,475

Per share 3,233,750× higher

Bitcoin $1.72T

$356,382.59

Per share 183,702× higher

Nvidia $5.48T

$1,135,552

Per share 585,336× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for Alzamend Neuro are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.